NGNE
Neurogene Inc.
A biotechnology company that engineers gene therapies for rare, severe neurological diseases, mostly affecting children, such as Rett syndrome. Its EXACT technology acts like a built-in dial, fine-tuning how much of a therapeutic protein a cell makes to avoid the toxicity that often plagues conventional gene therapy. The company was founded in 2018 by Rachel McMinn, a biotech analyst whose older brother lives with an undiagnosed neurological condition—the personal spark behind the whole venture—and it went public in 2023 through a reverse merger.
CUSIP: 64135M105HealthcareUS1 holder
Total Value
$10.77M
Total Shares
342.5K
Net Share Change
-182.3K
Activity
1 selling
Investor
Value
Shares
Weight
Change
